Overprescription of antibiotics is one of the causes of the increasing incidence of antibiotic resistance. Bacteria are constantly evolving and able to develop resistance to new antibiotics by producing β-lactamases, thus causing the standard treatments to be ineffective. Furthermore, genes for antibiotic resistance can be transferred between unrelated species. β-Lactamases are classified into serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs). Clavulanic acid is a well-known inhibitor that can effectively inhibit serine β-lactamases (SBLs). Nonetheless, society is in urgent In this research, novel inhibitors against IMP-1 MBL were designed based on the excellent competitive inhibition properties of L-captopril and D-captopril, compound RS-4.2, and compound 5.1. Modelling studies were done by docking these newly designed molecules into IMP-1 enzyme (PDB code: 1JJT) using Molegro Virtual Docker (MVD) software. Thiolate group of the designed compounds was predicted to bind to both zinc ions and the carboxylate and amide carbonyl groups of the compounds were predicted to form hydrogen bond or electrostatic interactions with the amino acid residues of the IMP-1 active site. Due to these favourable interactions, the MVD software predicted that the designed compounds would have high inhibition potencies against the enzyme.Syntheses of the designed molecules were completed via esterification of the starting materials, coupling reaction and lastly hydrolysis to remove both methyl ester and thioester. Eight series of compounds were synthesised including L-and D-proline derivatives (thiols and dicarboxylic acids), D-captopril derivatives, pipecolinic acid derivatives, phenylglycine derivatives, 2-aminopyridine derivatives, 2-amino-6-picolinic acid derivatives and diaminobenzoic acid derivatives. All of the